Fig. 4From: Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case reportPost-infusion serum soluble BCMA level over time. CAR, chimeric antigen receptor; BCMA, B-cell maturation antigenBack to article page